#NewAseBioMember | “AseBio is a strategic opportunity to connect with the national and international biotechnology ecosystem”

AseBio. What does your company's work contribute, and what is its strength?

Alfonso de Egaña. At Molefy Pharma, we work with a very clear goal: to find a cure for ALS. All of our scientific, strategic, and business activities are aligned with this mission.

We bring to the biotechnology sector a commitment to develop new, innovative treatments for a disease that currently has no cure. Our biomedical research focuses on addressing the biological mechanisms that cause the disease, not just alleviating its symptoms, with the aim of making a real and transformative impact on patients' lives.

AseBio. What does AseBio mean to you?

Alfonso de Egaña. AseBio is a strategic opportunity to connect with the national and international biotechnology ecosystem. It is a meeting point for companies, research centers, and key players who can help us continue to grow and accelerate our developments.

AseBio. When did you first hear about AseBio?

Alfonso de Egaña. We had known about AseBio for some time due to its important role in the biotech sector in Spain, but our first close, personal contact was approximately one year ago, during Transfiere. That meeting allowed us to learn more about its work and understand the value it brings as a platform for connecting and promoting the sector.

AseBio. What do you expect from being part of an association such as AseBio?

Alfonso de Egaña. We hope to stay informed and connected with opportunities in the sector. We particularly value the work done by AseBio in publicizing calls for proposals, grants, and funding opportunities, which is essential for innovative companies like ours.

We also want it to help us raise our profile, expand our network of contacts, and generate new strategic partnerships. In a sector such as biotechnology, collaboration is key to progress, especially in areas such as clinical trials in Spain and the development of new treatments.

AseBio. What is the biggest challenge facing the biotech sector or your company?

Alfonso de Egaña. In the case of Molefy Pharma, our greatest challenge is to advance toward a cure for ALS. It is a devastating disease, with an urgent need for new therapeutic solutions, and we are committed to developing a treatment that can change its prognosis.

To achieve this, one of the main challenges is securing the necessary funding to complete all clinical phases. Drug development is a long, complex, and highly demanding process from a regulatory and scientific standpoint.